Paragon Biosciences ^Investors

Paragon Biosciences is a global healthcare company that focuses on accelerating biomedical research and solving complex challenges in the field of life science innovation. They are committed to advancing science and have a portfolio of companies in various areas such as artificial intelligence, gene therapy, synthetic biology, and biopharmaceuticals. Some of their notable achievements include Harmony Biosciences, which developed and commercialized the first nonscheduled treatment for narcolepsy, and Emalex Biosciences, which is in late-stage development of a new class of drug for patients with Tourette syndrome. Paragon Biosciences was founded in 2010 and is headquartered in Northbrook, Illinois.